Tumor-specific Th17-polarized cells eradicate large established melanoma.

CD4+ T cells can differentiate into multiple effector subsets, but the potential roles of these subsets in anti-tumor immunity have not been fully explored. Seeking to study the impact of CD4+ T cell polarization on tumor rejection in a model mimicking human disease, we generated a new MHC class II-restricted, T-cell receptor (TCR) transgenic mouse model in which CD4+ T cells recognize a novel epitope in tyrosinase-related protein 1 (TRP-1), an antigen expressed by normal melanocytes and B16 murine melanoma. Cells could be robustly polarized into Th0, Th1, and Th17 subtypes in vitro, as evidenced by cytokine, chemokine, and adhesion molecule profiles and by surface markers, suggesting the potential for differential effector function in vivo. Contrary to the current view that Th1 cells are most important in tumor rejection, we found that Th17-polarized cells better mediated destruction of advanced B16 melanoma. Their therapeutic effect was critically dependent on interferon-gamma (IFN-gamma) production, whereas depletion of interleukin (IL)-17A and IL-23 had little impact. Taken together, these data indicate that the appropriate in vitro polarization of effector CD4+ T cells is decisive for successful tumor eradication. This principle should be considered in designing clinical trials involving adoptive transfer-based immunotherapy of human malignancies.

[1]  R. Xavier,et al.  IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. , 2008, The Journal of clinical investigation.

[2]  J. O’Shea,et al.  Regulation of IL-17 production in human lymphocytes. , 2008, Cytokine.

[3]  Yuka Kanno,et al.  Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. , 2008, Blood.

[4]  L. Fouser,et al.  IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. , 2008, The Journal of clinical investigation.

[5]  D. Douek,et al.  IFN-γ Mediates the Death of Th1 Cells in a Paracrine Manner1 , 2008, The Journal of Immunology.

[6]  D. Littman,et al.  Transcriptional regulation of Th17 cell differentiation. , 2007, Seminars in immunology.

[7]  J. O’Shea,et al.  Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. , 2007, Seminars in immunology.

[8]  Lai Wei,et al.  IL-21 Is Produced by Th17 Cells and Drives IL-17 Production in a STAT3-dependent Manner* , 2007, Journal of Biological Chemistry.

[9]  R. Komorowski,et al.  Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. , 2007, Blood.

[10]  A. Murphy,et al.  Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. , 2007, Immunity.

[11]  D. Levy,et al.  IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways , 2007, Nature Immunology.

[12]  A. Intlekofer,et al.  Brief Definitive Report , 2022 .

[13]  L. Cosmi,et al.  Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.

[14]  F. Sallusto,et al.  Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells , 2007, Nature Immunology.

[15]  Terry B. Strom,et al.  IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells , 2007, Nature.

[16]  A. Billiau,et al.  Experimental and clinical approaches for optimization of the graft-versus-leukemia effect , 2007, Nature Clinical Practice Oncology.

[17]  Y. Iwakura,et al.  Systemic Administration of IL-23 Induces Potent Antitumor Immunity Primarily Mediated through Th1-Type Response in Association with the Endogenously Expressed IL-121 , 2007, The Journal of Immunology.

[18]  Brigitta Stockinger,et al.  Differentiation and function of Th17 T cells. , 2007, Current opinion in immunology.

[19]  A. Chang,et al.  Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment1 , 2007, The Journal of Immunology.

[20]  A. O’Garra,et al.  TH1 cells control themselves by producing interleukin-10 , 2007, Nature Reviews Immunology.

[21]  R. Nussenblatt,et al.  TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1 , 2007, Nature Medicine.

[22]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[23]  R. Kastelein,et al.  Swords into plowshares: IL-23 repurposes tumor immune surveillance. , 2007, Trends in immunology.

[24]  R. D. Hatton,et al.  IL-17 family cytokines and the expanding diversity of effector T cell lineages. , 2007, Annual review of immunology.

[25]  G. Trinchieri,et al.  Interleukin-10 production by effector T cells: Th1 cells show self control , 2007, The Journal of experimental medicine.

[26]  S. Suryani,et al.  An interferon-γ-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis , 2007, Journal of Neuroimmunology.

[27]  A. Lovett-racke,et al.  T-bet Regulates the Fate of Th1 and Th17 Lymphocytes in Autoimmunity1 , 2007, The Journal of Immunology.

[28]  A. Abbas,et al.  Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease , 2006, The Journal of experimental medicine.

[29]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[30]  D. Littman,et al.  The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells , 2006, Cell.

[31]  D. Farkas,et al.  Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. , 2006, Cancer research.

[32]  M. Kurrer,et al.  T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17 , 2006, The Journal of experimental medicine.

[33]  T. Mcclanahan,et al.  IL-23 promotes tumour incidence and growth , 2006, Nature.

[34]  C. Murre,et al.  Interplay between RORgammat, Egr3, and E proteins controls proliferation in response to pre-TCR signals. , 2006, Immunity.

[35]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[36]  R. D. Hatton,et al.  Transforming growth factor-β induces development of the TH17 lineage , 2006, Nature.

[37]  Anna M. Keller,et al.  Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant1 , 2006, The Journal of Immunology.

[38]  Jane Loveland,et al.  Genomic anatomy of the Tyrp1 (brown) deletion complex. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[40]  O. Lantz,et al.  CD4 cells can be more efficient at tumor rejection than CD8 cells. , 2005, Blood.

[41]  M. Lotze,et al.  IL-17 Enhances the Net Angiogenic Activity and In Vivo Growth of Human Non-Small Cell Lung Cancer in SCID Mice through Promoting CXCR-2-Dependent Angiogenesis1 , 2005, The Journal of Immunology.

[42]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[43]  R. Offringa,et al.  CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts. , 2005, Cancer research.

[44]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[45]  M. Zanetti,et al.  CD4 T cells in tumor immunity , 2005, Springer Seminars in Immunopathology.

[46]  Guttorm Haraldsen,et al.  Primary antitumor immune response mediated by CD4+ T cells. , 2005, Immunity.

[47]  N. Restifo,et al.  CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. , 2005, Journal of immunotherapy.

[48]  A. Rudensky,et al.  Regulatory T cell lineage specification by the forkhead transcription factor foxp3. , 2005, Immunity.

[49]  S. Rosenberg,et al.  CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.

[50]  G. Inghirami,et al.  Tim-3+ T-bet+ Tumor-Specific Th1 Cells Colocalize with and Inhibit Development and Growth of Murine Neoplasms1 , 2005, The Journal of Immunology.

[51]  K. Knutson,et al.  Tumor antigen-specific T helper cells in cancer immunity and immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[52]  A. Ochsenbein Immunological ignorance of solid tumors , 2005, Springer Seminars in Immunopathology.

[53]  A. Lovett-racke,et al.  Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. , 2004, Immunity.

[54]  E. Tartour,et al.  Expression and activity of IL‐17 in cutaneous T‐cell lymphomas (mycosis fungoides and sezary syndrome) , 2004, International journal of cancer.

[55]  S. Szabo,et al.  Loss of T-bet, But Not STAT1, Prevents the Development of Experimental Autoimmune Encephalomyelitis , 2004, The Journal of experimental medicine.

[56]  P. Allen,et al.  CD4-Directed Peptide Vaccination Augments an Antitumor Response, but Efficacy Is Limited by the Number of CD8+ T Cell Precursors1 , 2004, The Journal of Immunology.

[57]  J. Van Damme,et al.  The CC chemokine CCL20 and its receptor CCR6. , 2003, Cytokine & growth factor reviews.

[58]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[59]  G. Steiner,et al.  Expression and function of pro‐inflammatory interleukin IL‐17 and IL‐17 receptor in normal, benign hyperplastic, and malignant prostate , 2003, The Prostate.

[60]  M. Lotze,et al.  Interleukin-17 promotes angiogenesis and tumor growth. , 2003, Blood.

[61]  P. Foster,et al.  Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells , 2003, The Journal of experimental medicine.

[62]  I. Frazer,et al.  Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. , 2002, Cancer research.

[63]  E. Tartour,et al.  Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. , 2002, Blood.

[64]  S. Khoury,et al.  Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. , 2001, The Journal of clinical investigation.

[65]  F. Zhang,et al.  Retinoid-related orphan receptor γ (RORγ) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis , 2000 .

[66]  A. Pierani,et al.  Requirement for RORgamma in thymocyte survival and lymphoid organ development. , 2000, Science.

[67]  T. Blankenstein,et al.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.

[68]  A. Ohta,et al.  Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo , 1999, The Journal of experimental medicine.

[69]  J. Banchereau,et al.  Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. , 1999, Cancer research.

[70]  R. Schreiber,et al.  CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ , 1999 .

[71]  B. Moss,et al.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[72]  P. Klenerman,et al.  Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[73]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[74]  M. Bevan,et al.  RORgamma t, a novel isoform of an orphan receptor, negatively regulates Fas ligand expression and IL-2 production in T cells. , 1998, Immunity.

[75]  P. Möller,et al.  T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. , 1998, Journal of immunology.

[76]  B. Bogen,et al.  Naive CD4+ T cells confer idiotype‐specific tumor resistance in the absence of antibodies , 1995, European Journal of Immunology.

[77]  D. Pardoll,et al.  In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression , 1994, The Journal of experimental medicine.

[78]  B. Bogen,et al.  The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. , 1993, Cellular immunology.

[79]  H. Fujiwara,et al.  The role of tumor-specific Lyt-1+2− T cells in eradicating tumor cells in vivo , 1987, Cancer Immunology, Immunotherapy.

[80]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.

[81]  M. Cheever,et al.  Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells , 1985, The Journal of experimental medicine.

[82]  M. Fukuzawa,et al.  The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. , 1984, Journal of immunology.

[83]  D. Douek,et al.  IFN-gamma mediates the death of Th1 cells in a paracrine manner. , 2008, Journal of immunology.

[84]  Ncbi National Center for Biotechnology Information , 2008 .

[85]  J. O’Shea,et al.  T(H)-17 differentiation: of mice and men. , 2007, Nature Immunology.

[86]  L. Cosmi,et al.  Phenotypic and functional features of human Th 17 cells , 2007 .

[87]  F. Sallusto,et al.  Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. , 2007, Nature immunology.

[88]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[89]  K. Knutson,et al.  Cancer Immunol Immunother DOI 10.1007/s00262-006-0194-y REVIEW , 2006 .

[90]  D. Littman,et al.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. , 2006, Cell.

[91]  D. Higgs,et al.  Articles on similar topics can be found in the following Blood collections , 2002 .

[92]  N. Shastri,et al.  Generation of antigen-specific, lacZ-inducible T-cell hybrids. , 2001, Methods in molecular biology.

[93]  G. Plautz,et al.  CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. , 2000, Critical reviews in immunology.

[94]  D. Patel,et al.  Retinoid-related orphan receptor gamma (RORgamma) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[95]  A. Ohta,et al.  The critical role of Th1-dominant immunity in tumor immunology , 2000, Cancer Chemotherapy and Pharmacology.

[96]  U. Boehm,et al.  Cellular responses to interferon-gamma. , 1997, Annual review of immunology.

[97]  J. Barrett,et al.  The allogeneic CD4+ T-cell-mediated graft-versus-leukemia effect. , 1997, Leukemia & lymphoma.